HRGN — Harvard Apparatus Regenerative Technology, Inc.

—
OTC · Health Care · Health Care Equipment & Supplies · CIK 1563665 ·
Last close
$1.90
Market Cap
$38.54M
52W High
$2.46
52W Low
$0.96
ADV30
3,583
Next earnings
—
Harvard Apparatus Regenerative Technology Inc., a clinical-stage biotechnology company, focuses on developing regenerative-medicine treatments for disorders of the gastro-intestinal system and other organs resulting from cancer, trauma, or birth defects. The company's lead product candidate is Cellspan Esophageal Implant for the treatment of severe esophageal disease. It's pipeline includes organ-regeneration technology for the repair or replacement of diseased or damaged organs; and product candidates to treat conditions of the esophagus, including traumatic injury, caustic burns, tissue damage following chemoradiation therapy, birth defects, and reconstruction of the colon and uterus wound repair. The company also sells consumer health products that focuses on personal healthcare, including dietary supplements. Harvard Apparatus Regenerative Technology Inc. was formerly known as Biostage, Inc. and changed its name to Harvard Apparatus Regenerative Technology Inc. in July 2023. The company was founded in 2009 and is headquartered in Holliston, Massachusetts.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 145,000 12,000 -1,460,000 -1,463,000 3,169,000 1,851,000 2,647,000
Jun 2026 414,000 23,000 -1,692,000 -1,695,000 1,685,000 351,000 3,064,000
Mar 2026 226,000 20,000 -1,606,000 -1,601,000 1,798,000 419,000 1,706,000
Dec 2025 219,000 20,000 -1,698,000 -1,687,000 2,677,000 1,352,000 1,620,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-3,635,000
Investing CF
—
Financing CF
$2,700,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.40
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-109,853,000
Inventory
$0
Receivables
$9,000
ST Investments
—
EBIT TTM
$-6,670,000
Pretax Income TTM
$-6,683,000
Interest Exp TTM
$13,000
Analysts
—

Yahoo Snapshot (yfinance, live)

Total Revenue
$982,000
EBITDA
$-6,706,000
Free Cash Flow
$-1,065,875
Enterprise Value
$34,752,260
Total Cash
$351,000
Total Debt
$645,000
Shares Out
20,284,471
Trailing EPS
$-0.39
Book Value
$-0.08
ROE
-636.5%
ROA
-219.5%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 704,000 -6,915,000 -6,869,000 2,677,000 1,620,000 1,057,000 -3,828,000
Dec 2024 430,000 -7,726,000 -7,732,000 4,442,000 1,220,000 3,222,000 -4,852,000
Dec 2023 103,000 -8,990,000 -8,945,000 2,614,000 968,000 1,646,000 -6,939,000
Dec 2022 0 -6,153,000 -6,073,000 2,400,000 1,411,000 989,000 -5,106,000

TTM Snapshot

Revenues TTM
$982,000
NetIncome TTM
$-6,683,000
OpCashFlow TTM
—
Assets (Latest)
$1,685,000
Forward EPS
—

Peers — same industry

TickerNameMarket CapLastDaily %
MCAG Mountain Crest Acquisition Corp. V $38.13M $13.27 —
SRTS Sensus Healthcare, Inc. $37.20M $2.26 —
NXGL NEXGEL, INC. $37.04M $3.80 —
MYO MYOMO, INC. $36.85M $0.92 —
ADGM Adagio Medical Holdings, Inc. $36.65M $1.65 —

Recent Insider Activity

No insider activity indexed for this ticker.